Imatinib is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, which is present in chronic myeloid leukemia/CML cells [236,237]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.